Clinical Trial Detail

NCT ID NCT01211457
Title Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Cyclacel Pharmaceuticals, Inc.
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Sapacitabine + Venetoclax

Decitabine + Sapacitabine

Age Groups: senior adult

No variant requirements are available.